{"prompt": "['MC1752', '1', 'Mayo Clinic Cancer Center', 'Phase II study evaluating combination chemotherapy + Radiotherapy (RT) with avelumab in', 'muscle invasive bladder cancer.', 'Sponsor/Principal Investigator: Parminder Singh, MD', 'Mayo Clinic', '5777 E. Mayo Blvd', 'Phoenix, AZ 85054', '480-301-8000 (Phone)', '480-301-4675 (FAX)', 'Co-Principal Investigators:', 'Co-Investigators:', 'Statistician:', 'FDA IND #: 139335', 'Trial Supported by:', 'Funding: EMD Serono', 'Drug Availability:', 'Commercial Agents: 5 - Flourouracil, mitomycin, cisplatin', 'Drug Company Supplied: avelumab', 'NStudy contributor(s) not responsible for patient care', 'Protocol Version Date: 21JUN2018']['MC1752', '2', 'Document History', '(Effective Date)', 'Activation', '19Sep2018', 'Protocol Resources', 'Questions:', 'Contact Name:', 'Patient eligibility*, test schedule,', 'Data Manager', 'treatment delays/interruptions/adjustments,', 'Phone:', 'dose modifications, adverse events,', 'forms completion and submission', 'Forms completion and submission', '(Arizona Coordinator)', 'Phone:', '(Arizona Data Coordinator)', 'Phone:', 'Protocol document, consent form,', 'Sr. Research Protocol Specialist', 'regulatory issues', 'Serious Adverse Event Reporting', 'SAE Coordinator', '*No waivers of eligibility allowed', 'Protocol Version Date: 21JUN2018']['MC1752', '3', 'Table of Contents', 'Phase II study evaluating combination chemotherapy + Radiotherapy (RT) with avelumab in', 'muscle invasive bladder cancer.', '1', 'Protocol Resources', '2', 'Table of Contents', '3', '1.0', 'Background', '5', '2.0', 'Goals', '12', '3.0', 'Registration Patient Eligibility', '13', '4.0', 'Test Schedule', '16', '5.0', 'Grouping Factor:', '19', '6.0', 'Registration Procedures', '19', '7.0', 'Protocol Treatment', '22', '8.0', 'Dosage Modification Based on Adverse Events', '27', '9.0', 'Ancillary Treatment/Supportive Care', '37', '10.0', 'Adverse Event (AE) Monitoring and Reporting', '43', '11.0', 'Treatment Evaluation', '52', '12.0', 'Descriptive Factors:', '53', '13.0', 'Treatment/Follow-up Decision at Evaluation of Patient', '53', '14.0', 'Body Fluid Biospecimens', '55', '15.0', 'Drug Information', '55', '16.0', 'Statistical Considerations and Methodology', '64', '17.0', 'Pathology Considerations/Tissue Biospecimens', '70', '18.0', 'Records and Data Collection Procedures', '72', '19.0', 'Budget Considerations', '72', '20.0', 'References', '73', 'Appendix I', 'ECOG Performance Status', '75', 'Appendix II', 'EORTC QLQ-C30', '76', 'Appendix III', 'EORTC QLQ-BLM30', '78', 'Appendix IV', 'Patient Information Sheet', '81', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}